We are live on ! Find out more
FGP

Foyston, Gordon, & Payne Portfolio holdings

AUM $434M
1-Year Est. Return 9.09%
This Fund
S&P 500
This Quarter Est. Return
+0.58%
1 Year Est. Return
+9.09%
3 Year Est. Return
+56.86%
5 Year Est. Return
+84.63%
10 Year Est. Return
+238.52%
AUM
$400M
AUM Growth
-$20.2M
Cap. Flow
-$22M
Cap. Flow %
-5.5%
Top 10 Hldgs %
46.21%
Holding
64
New
1
Increased
13
Reduced
36
Closed
6

Top Buys

Rank Stock Value
1
GNTX icon
Gentex
GNTX
+$2.44M
2
BKNG icon
Booking.com
BKNG
+$1.65M
3
BDX icon
Becton Dickinson
BDX
+$816K
4
CTVA icon
Corteva
CTVA
+$740K
5
BAX icon
Baxter International
BAX
+$729K

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$3.98M
2
MSI icon
Motorola Solutions
MSI
+$3.05M
3
DOX icon
Amdocs
DOX
+$3.01M
4
SWK icon
Stanley Black & Decker
SWK
+$2.46M
5
MMM icon
3M
MMM
+$1.87M

Sector Composition

Rank Sector Weight
1 Technology 24.16%
2 Healthcare 22.24%
3 Industrials 16.47%
4 Consumer Staples 11.13%
5 Consumer Discretionary 10.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UNP icon
26
Union Pacific
UNP
$174B
$5.19M 1.3%
26,491
-1,941
-7% -$419K
RTX icon
27
RTX Corp
RTX
$290B
$5.15M 1.29%
59,889
+47
+0.1% +$4.02K
SONY icon
28
Sony
SONY
$137B
$5.03M 1.26%
227,500
+13,060
+6% +$273K
AOS icon
29
A.O. Smith
AOS
$8.17B
$4.93M 1.23%
80,785
-6,195
-7% -$433K
KO icon
30
Coca-Cola
KO
$377B
$4.92M 1.23%
93,720
CPRT icon
31
Copart
CPRT
$27B
$4.92M 1.23%
141,720
-11,956
-8% -$427K
ROST icon
32
Ross Stores
ROST
$80.5B
$4.56M 1.14%
41,883
-2,682
-6% -$321K
ULTA icon
33
Ulta Beauty
ULTA
$22B
$4.51M 1.13%
12,504
-910
-7% -$329K
BRK.B icon
34
Berkshire Hathaway Class B
BRK.B
$1.1T
$4.46M 1.11%
16,323
PFE icon
35
Pfizer
PFE
$143B
$4.04M 1.01%
93,997
-36,116
-28% -$1.6M
CME icon
36
CME Group
CME
$96.3B
$3.72M 0.93%
19,217
+120
+0.6% +$24.3K
BDX icon
37
Becton Dickinson
BDX
$45.6B
$3.71M 0.93%
15,491
+3,328
+27% +$816K
NVS icon
38
Novartis
NVS
$297B
$3.54M 0.88%
43,289
-230
-0.5% -$20.7K
VVV icon
39
Valvoline
VVV
$4.9B
$3.44M 0.86%
110,158
+15,614
+17% +$484K
ALSN icon
40
Allison Transmission
ALSN
$9.5B
$3.42M 0.85%
96,853
-668
-0.7% -$25.5K
TRU icon
41
TransUnion
TRU
$15.1B
$3.35M 0.84%
29,781
-2,787
-9% -$328K
AXTA icon
42
Axalta
AXTA
$7.66B
$3.31M 0.83%
113,525
-74
-0.1% -$2.21K
WMT icon
43
Walmart Inc
WMT
$885B
$2.78M 0.69%
59,850
SNY icon
44
Sanofi
SNY
$103B
$2.28M 0.57%
47,361
-965
-2% -$49.1K
RELX icon
45
RELX
RELX
$61.8B
$2.24M 0.56%
77,537
-2,424
-3% -$71.4K
CDW icon
46
CDW
CDW
$18.9B
$2.16M 0.54%
11,851
-111
-0.9% -$21K
UL icon
47
Unilever
UL
$137B
$1.6M 0.4%
26,254
+168
+0.6% +$10.7K
TJX icon
48
TJX Companies
TJX
$174B
$1.55M 0.39%
23,499
-229
-1% -$16K
ABT icon
49
Abbott
ABT
$183B
$1.44M 0.36%
12,200
SBUX icon
50
Starbucks
SBUX
$120B
$1.32M 0.33%
11,947
-4,723
-28% -$553K

Similar funds

Foyston, Gordon, & Payne's Q3 2021 Portfolio in Review

As of Q3 2021, Foyston, Gordon, & Payne held 64 positions worth $400M, down 4.8% from $420M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Foyston, Gordon, & Payne withdrew a net $22M in Q3 2021, closing 6 positions and reducing 36 holdings. Its most notable exit was Amdocs, an estimated $3.01M position sold in full.

By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 24% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Foyston, Gordon, & Payne opened a new position in US Bancorp worth $206K.

  • Foyston, Gordon, & Payne's largest Q3 2021 buy was US Bancorp: 3,463 shares worth $206K.
  • Foyston, Gordon, & Payne added most to Gentex in Q3 2021, an estimated $2.44M increase.
  • Foyston, Gordon, & Payne's biggest Q3 2021 reduction was Microsoft, cutting an estimated $3.98M.
  • Foyston, Gordon, & Payne fully exited Amdocs in Q3 2021, selling an estimated $3.01M.
  • Foyston, Gordon, & Payne's ten largest holdings make up 46% of its $400M portfolio in Q3 2021.
  • Foyston, Gordon, & Payne opened 1 new position and closed 6 in Q3 2021.
  • Foyston, Gordon, & Payne's portfolio value fell 4.8% quarter-over-quarter to $400M.

Based on Foyston, Gordon, & Payne's 13F filing for Q3 2021, filed 12 Nov 2021.